Lynk Pharmaceuticals Announces NMPA Acceptance of New Drug Application for Zemprocitinib in the Treatment of Rheumatoid Arthritis

Lynk Pharmaceuticals, a clinical-stage drug developer focused on immune and inflammatory diseases, announced that a New Drug Application for a core program had been filed or submitted; the provided article text cuts off before identifying the program or giving further details. No regulatory outcome, timing, or market reaction is provided.